<DOC>
	<DOC>NCT00998985</DOC>
	<brief_summary>This multiple dose study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of grazoprevir (MK-5172) in Genotype (GT) 1 and GT3 Hepatitis C virus (HCV)- infected participants. The primary hypothesis is that administration of grazoprevir for 7 days is sufficiently safe and well tolerated in HCV-infected males.</brief_summary>
	<brief_title>A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Baseline health is stable. Has a clinical diagnosis of chronic HCV infection. Has a history of stroke or chronic seizures. Has a history of cancer. Has a history of human immunodeficiency virus (HIV) infection. Has had major surgery, donated blood or participated in another investigational study within the past 3 months.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>